Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Theravance Biopharma Announces First Patient Dosed in TD-1473 Study

americanpharmaceuticalreviewDecember 27, 2018

Tag: Theravance Biopharma , TD-1473 , JAK inhibitor , inflammatory intestinal diseases

PharmaSources Customer Service